Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record, with a small difference in title or year; 34 of the 34 references it cites were found in a registry or an index.

Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial

Open access
Ito, Sadayoshi, Shikata, Kenichi, Nangaku, Masaomi, Okuda, Yasuyuki, Sawanobori, Tomoko · 2019 · Clinical Journal of the American Society of Nephrology

Abstract

Background and objectives: The progression of kidney disease in some patients with type 2 diabetes mellitus may not be adequately suppressed by renin-angiotensin system inhibitors. Esaxerenone (CS-3150) is a nonsteroidal mineralocorticoid receptor blocker that has shown kidney protective effects in preclinical studies, and it is a potential add-on therapy to treat diabetic kidney disease. This phase 2 study evaluated the efficacy and safety of esaxerenone in Japanese patients with type 2 diabetes mellitus and microalbuminuria. Design, setting, participants, & measurements: This multicenter, randomized, double-blind, placebo-controlled trial enrolled 365 hypertensive or normotensive patients with type 2 diabetes mellitus and microalbuminuria (urinary albumin-to-creatinine ratio ≥45 to <300 mg/g creatinine) treated with renin-angiotensin system inhibitor who had eGFR≥30 ml/min per 1.73 m 2 . Participants were randomized to receive 0.625, 1.25, 2.5, or 5 mg/d esaxerenone or placebo for 12 weeks. The primary end point was the change in urinary albumin-to-creatinine ratio from baseline to week 12 (with last observation carried forward). Results: Esaxerenone treatment at 1.25, 2.5, and 5 mg/d significantly reduced urinary albumin-to-creatinine ratio by the end of treatment (38%, 50%, and 56%, respectively) compared with placebo (7%; all P <0.001). The urinary albumin-to-creatinine ratio remission rate (defined as urinary albumin-to-creatinine ratio <30 mg/g creatinine at the end of treatment and ≥30% decrease from baseline) was 21% in the 2.5- and 5-mg/d groups versus 3% for placebo (both P <0.05). Adverse events occurred slightly more frequently with esaxerenone versus placebo, but the frequencies of drug-related adverse events and discontinuation rates were similar in the placebo and the 0.625-, 1.25-, and 2.5-mg/d groups. Drug-related adverse events and treatment discontinuations were marginally higher in the 5-mg/d group. The most common drug-related adverse event was hyperkalemia, which was dose proportional. Conclusions: Adding esaxerenone at 1.25, 2.5, and 5 mg/d for 12 weeks to an ongoing renin-angiotensin system inhibitor significantly reduces urinary albumin-to-creatinine ratio in patients with type 2 diabetes mellitus and microalbuminuria.

Overview

Integrity signals

Registry

Crossref · 10.2215/cjn.14751218

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 34 references

Cited by

See all 107

Metadata

Authors
Ito, S., Shikata, K., Nangaku, M., Okuda, Y., & Sawanobori, T.
Affiliations
  • Tohoku University (JP)
  • Okayama University Hospital (JP)
  • The University of Tokyo (JP)
  • Biostatistics and Data Management Department, and
  • Daiichi-Sankyo (Japan) (JP)
Corresponding author
Ito, Sadayoshi
Venue
Clinical Journal of the American Society of Nephrology
Published
2019-06-27
Volume
14
Issue
8
Pages
1161-1172
ISSN
  • 1555-9041 (ISSN-L)
  • 1555-905X
OpenAlex
W2954234894
Cited by
107
References
34
Citations by year
2026: 5 · 2025: 9 · 2024: 8 · 2023: 24 · 2022: 17 · 2021: 23 · 2020: 19 · 2019: 2
FWCI
11.76
Type
journal article
Language
en
Open access
Locations
  • Clinical Journal of the American Society of Nephrology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
Daiichi-Sankyo
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
  • Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
Keywords
esaxerenone, type 2 diabetes, microalbuminuria, diabetic nephropathy, mineralocorticoid receptor antagonists, renin-angiotensin system inhibitors, albumin-creatinine ratio, hyperkalemia, drug safety, Japanese patients, adjunctive therapy, EGFR, hypertension, renin-angiotensin system blockade
MeSH terms
Aged, Albuminuria, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Female, Humans, Male, Middle Aged, Pyrroles, Sulfones, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial. https://app.cochat.ai/papers/10.2215/cjn.14751218
The paper
Ito, S., Shikata, K., Nangaku, M., Okuda, Y., & Sawanobori, T. (2019). Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.14751218

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.